VASO Corp.
- VASO · OTC
- Electromedical & Electrotherapeutic Apparatus
- Plainview, NY
- 282 employees
- CIK 0000839087
Updated from SEC filings through
Top things to know
Executives
- Jun Ma President, Chief Executive Officer and Director 10-K, 2026-03-31
- Jonathan P. Newton Chief Financial Officer, Treasurer and Secretary 10-K, 2026-03-31
- Jane Moen President of VasoHealthcare, Chief Operating Officer 10-K, 2026-03-31
- Peter C. Castle President of VasoTechnology 10-K, 2026-03-31
- Edgar Rios Vice Chairman of the Board and Director 10-K, 2026-03-31
VASO Corp is a U.S. public company in electromedical & electrotherapeutic apparatus (SIC 3845), headquartered in Plainview, NY. It trades as VASO on OTC. Revenue was $89.1M in the fiscal year ending December 31, 2025, +2.7% from the year before. It reported about 282 employees. Jun Ma is President, Chief Executive Officer and Director.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $89.1M 10-K, 2026-03-31 | $86.8M 10-K, 2026-03-31 | $81.0M 10-K, 2025-03-31 | $79.3M 10-K, 2024-04-01 | $75.6M 10-K, 2023-03-31 |
| Operating income | -$2.9M 10-K, 2026-03-31 | $285K 10-K, 2026-03-31 | $4.2M 10-K, 2025-03-31 | $6.5M 10-K, 2024-04-01 | $2.8M 10-K, 2023-03-31 |
| SG&A | $52.2M 10-K, 2026-03-31 | $49.0M 10-K, 2026-03-31 | $45.1M 10-K, 2025-03-31 | $40.8M 10-K, 2024-04-01 | $38.6M 10-K, 2023-03-31 |
| Net income | $1.6M 10-K, 2026-03-31 | $951K 10-K, 2026-03-31 | $4.8M 10-K, 2025-03-31 | $11.3M 10-K, 2024-04-01 | $6.1M 10-K, 2023-03-31 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jun Ma | President, Chief Executive Officer and Director | 10-K, 2026-03-31 |
| Jonathan P. Newton | Chief Financial Officer, Treasurer and Secretary | 10-K, 2026-03-31 |
| Jane Moen | President of VasoHealthcare, Chief Operating Officer | 10-K, 2026-03-31 |
| Peter C. Castle | President of VasoTechnology | 10-K, 2026-03-31 |
| Edgar Rios | Vice Chairman of the Board and Director | 10-K, 2026-03-31 |
| Behnam Movaseghi | Director | 10-K, 2026-03-31 |
| David Lieberman | Director | 10-K, 2026-03-31 |
| Leon Dembo | Director | 10-K, 2026-03-31 |
What VASO Corp does
Vaso Corporation (the “Company”) principally operates in three distinct business segments in the healthcare equipment and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 176.0 million (as of August 12, 2026) | 10-Q, August 14, 2026 |
|---|---|---|
| Public float | $12.8M (as of June 30, 2025) | 10-K, March 31, 2026 |
| Reportable segments | 3 (period ending June 30, 2026) | 10-Q, August 14, 2026 |
| Latest proxy statement | Meeting December 8, 2026 (filed October 29, 2026) | DEF 14A, October 29, 2026 |
| Auditor | Uhy LLP (Sterling Heights, Michigan) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-07-31
- Item 1.01 Entry into a material definitive agreement
- Item 2.01 Completion of acquisition or disposition of assets
- 8-K filed 2026-07-23
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-08
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-02-12
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- 8-K filed 2025-12-19
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2025-11-20
- Item 8.01 Other events
- 8-K filed 2025-01-03
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2024-09-19
- Item 1.02 Termination of a material definitive agreement
- Item 8.01 Other events
- 8-K filed 2024-09-10
- Item 5.07 Submission of matters to a vote of security holders
- Item 8.01 Other events
- 8-K filed 2024-08-28
- Item 8.01 Other events
Frequently asked questions about VASO Corp
- What does VASO Corp do?
- In its own words, from Item 1 of its 10-K: "Vaso Corporation (the “Company”) principally operates in three distinct business segments in the healthcare equipment and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments."
- What is VASO Corp's revenue?
- $89.1M for the fiscal year ending December 31, 2025, from its 10-K filed March 31, 2026.
- Is VASO Corp profitable?
- VASO Corp reported net income of $1.6M for the fiscal year ending December 31, 2025.
- How many employees does VASO Corp have?
- About 282 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of VASO Corp?
- Jun Ma, President, Chief Executive Officer and Director, as named in a 10-K filed March 31, 2026.
- Who is the CFO of VASO Corp?
- Jonathan P. Newton, Chief Financial Officer, Treasurer and Secretary, as named in a 10-K filed March 31, 2026.
- Where is VASO Corp headquartered?
- Plainview, NY.
- What is VASO Corp's stock ticker?
- VASO on OTC.
- What industry is VASO Corp in?
- Electromedical & Electrotherapeutic Apparatus, SIC code 3845.
- What is VASO Corp's website?
- vasocorporation.com.
- When does VASO Corp report earnings next?
- November 14, 2026. Source: estimate_10q_cadence.
- Is VASO Corp a public company?
- Yes. VASO Corp files with the SEC under CIK 0000839087 and trades as VASO.
- Who audits VASO Corp?
- Uhy LLP, Sterling Heights, Michigan, as named in its latest annual report (10-K).
- How many shares of VASO Corp are outstanding?
- 176.0 million shares as of August 12, 2026, from its 10-Q filed August 14, 2026.
- What is VASO Corp's public float?
- $12.8M as of June 30, 2025, as reported on the cover of its 10-K filed March 31, 2026.
- How many business segments does VASO Corp report?
- 3 reportable segments for the period ending June 30, 2026, from its 10-Q filed August 14, 2026.
- When is VASO Corp's annual shareholder meeting?
- December 8, 2026, per its proxy statement (DEF 14A) filed October 29, 2026.